XML 64 R44.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Information (Tables)
12 Months Ended
Dec. 31, 2018
Segment Reporting [Abstract]  
Revenues by Product
Product revenues, net consisted of the following:
 
2018
(as reported under ASC 606)
 
2017
(as reported under ASC 605)
 
2016
(as reported under ASC 605)
 
(in thousands)
SYMDEKO/SYMKEVI
$
768,657

 
$

 
$

ORKAMBI
1,262,166

 
1,320,850

 
979,590

KALYDECO
1,007,502

 
844,630

 
703,432

Other

 

 
610

      Total product revenues, net
$
3,038,325

 
$
2,165,480

 
$
1,683,632

Revenues and Property and Equipment by Location
Property and equipment, net by location consisted of the following:
 
As of December 31,
 
2018
 
2017
 
(in thousands)
United States
$
778,157

 
$
753,128

Outside of the United States
 
 
 
United Kingdom
30,496

 
31,279

Other
3,352

 
5,030

Total property and equipment, net outside of the United States
33,848

 
36,309

      Total property and equipment, net
$
812,005

 
$
789,437

Total revenues from external customers and collaborators by geographic region consisted of the following:
 
2018
(as reported under ASC 606)
 
2017
(as reported under ASC 605)
 
2016
(as reported under ASC 605)
 
(in thousands)
United States
$
2,365,079

 
$
1,986,786

 
$
1,321,807

Outside of the United States
 
 
 
 
 
Europe
543,179

 
420,317

 
320,456

Other
139,339

 
81,549

 
59,914

Total revenues outside of the United States
682,518

 
501,866

 
380,370

Total revenues
$
3,047,597

 
$
2,488,652

 
$
1,702,177

Significant Customers
Gross revenues and accounts receivable from each of the Company’s customers who individually accounted for 10% or more of total gross revenues and/or 10% or more of total gross accounts receivable consisted of the following:
 
Percent of Total Gross
Revenues
 
Percent of Gross Accounts Receivable
 
Year Ended December 31,
 
As of December 31,
 
2018
(as reported under
ASC 606)
 
2017
(as reported under
ASC 605)
 
2016
(as reported under
ASC 605)
 
2018
 
2017
Walgreen Co.
20
%
 
17
%
 
19
%
 
16
%
 
20
%
Accredo/Curascript
14
%
 
14
%
 
15
%
 
10
%
 
12
%
McKesson Corporation
14
%
 
<10
%
 
<10
%
 
16
%
 
<10
%
CVS/Caremark
n/a

 
<10
%
 
19
%
 
n/a

 
n/a